ArticleMicrobial biotechnology2018
Model-driven design of a minimal medium for Akkermansia muciniphila confirms mucus adaptation.
Article in Microbial biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 82 citations in OpenAlex.
- Mucin-degrading gut bacteria: context-dependent roles in intestinal homeostasis and disease.Gut microbes · 2026Review
- Unique adaptations in sulfatases underpin colonic mucin degradation by Akkermansia muciniphila.Nature microbiology · 2026Article
- Mucin Type Drives Composition and Mucin Glycan Degradation of an In Vitro Synthetic Microbial Community.Environmental microbiology · 2026Article
- Functional Proteins of Akkermansia Muciniphila: Impacts on Host Health and Metabolism.Probiotics and antimicrobial proteins · 2026Review
- High stability of the genome ofMicrobiology spectrum · 2026Article
- The synthetic estradiol analog E0703 enhancesmLife · 2026Article
- Time-resolved growth of diverse human-associatedMicrobiology spectrum · 2026Article
- Analysis and characterization of a novel metallophosphoesterase fromBiochemistry and biophysics reports · 2026Article
- Gut microbiota-associated metabolite N-acetyl-D-glucosamine alleviates systemic inflammatory responses induced by acute Toxoplasma gondii infection.PLoS neglected tropical diseases · 2026Article
- Breaking down barriers: is intestinal mucus degradation byInfection and immunity · 2025Review
- Akkermansia muciniphila: biology, microbial ecology, host interactions and therapeutic potential.Nature reviews. Microbiology · 2025Review
- Health Effects and Therapeutic Potential of the Gut MicrobeNutrients · 2025Review
- Comparative analysis of amino acid auxotrophies and peptidase profiles in non-dysbiotic and dysbiotic small intestinal microbiomes.Computational and structural biotechnology journal · 2025Article
- Effect of sheep placenta extract on D-galactose-induced aging mouse.Frontiers in pharmacology · 2025Article
- Exploring the resilience and stability of a defined human gut microbiota consortium: An isothermal microcalorimetric study.MicrobiologyOpen · 2024Article
- Enrichment and characterization of human-associated mucin-degrading microbial consortia by sequential passage.FEMS microbiology ecology · 2024Article
- Binding of Akkermansia muciniphila to mucin is O-glycan specific.Nature communications · 2024Article
- Article
- Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.Scientific reports · 2024Article
- Mechanism of 2'-fucosyllactose degradation by human-associatedJournal of bacteriology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abundance of the human intestinal symbiont Akkermansia muciniphila has found to be inversely correlated with several diseases, including metabolic syndrome and obesity. A. muciniphila is known to use mucin as sole carbon and nitrogen source. To study the physiology and the potential for therapeutic applications of this bacterium, we designed a defined minimal medium. The composition of the medium was based on the genome-scale metabolic model of A. muciniphila and the composition of mucin. Our results indicate that A. muciniphila does not code for GlmS, the enzyme that mediates the conversion of fructose-6-phosphate (Fru6P) to glucosamine-6-phosphate (GlcN6P), which is essential in peptidoglycan formation. The only annotated enzyme that could mediate this conversion is Amuc-NagB on locus Amuc_1822. We found that Amuc-NagB was unable to form GlcN6P from Fru6P at physiological conditions, while it efficiently catalyzed the reverse reaction. To overcome this inability, N-acetylglucosamine needs to be present in the medium for A. muciniphila growth. With these findings, the genome-scale metabolic model was updated and used to accurately predict growth of A. muciniphila on synthetic media. The finding that A. muciniphila has a necessity for GlcNAc, which is present in mucin further prompts the adaptation to its mucosal niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.